Crohn's disease (CD) presents a great challenge regarding treatment, considering that the best drugs available have very limited effectiveness.OBJECTIVE: To analyze the characteristics between groups of patients with Crohn's disease who had response versus had not/lost response to treatment with anti-TNF.METHOD: Retrospective study of patients with CD treated with IFX or ADA.RESULTS: We studied 72 patients with mean age of 35 years; 45 of them were treated with infliximab and 27 with adalimumab; 90% of women were respondents, compared to 10% who were not respondents/lost response, and 60% of men were respondents versus 40% who were not respondents/lost response; there was no difference between IFX and ADA with respect to response; 48 patien...
OBJECTIVE: The aim of this study was to assess our clinical experience with infliximab, a monoclonal...
BACKGROUND: Anti-TNF drugs are effective treatments for the management of Crohn's disease but treatm...
BACKGROUND: Almost 20% of patients with active Crohn's disease are refractory to conventional therap...
AbstractCrohn's disease (CD) presents a great challenge regarding treatment, considering that the be...
Crohn's disease (CD) presents a great challenge regarding treatment, considering that the best drugs...
OBJECTIVE: Infliximab is an effective treatment for refractory or fistulizing Crohn's disease (CD). ...
Background a nd A ims: I nfliximab (IFX), adalimumab (ADA)and certolizumab pegol (CZP) have similar ...
Background and Aims: The three anti-TNF agents infliximab (IFX), adalimumab (ADA) andcertolizumab pe...
BACKGROUND: Infliximab (IFX), adalimumab (ADA), and certolizumab pegol (CZP) have similar efficacy i...
© 2018 Nik Sheng DingCrohn’s disease is a chronic, disabling inflammatory condition that affects the...
Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and...
The arrival of anti-tumor necrosis factor (TNF) agents has led to a dramatic improvement in the care...
BACKGROUND: Anti-TNF drugs are effective treatments for the management of Crohn's disease but treatm...
INTRODUCTION: There is currently an increasing use of biological agents in the management of Crohn's...
Objectives: Crohn’s disease is a chronic, relapsing inflammatory disease of the gastro-intestinal tr...
OBJECTIVE: The aim of this study was to assess our clinical experience with infliximab, a monoclonal...
BACKGROUND: Anti-TNF drugs are effective treatments for the management of Crohn's disease but treatm...
BACKGROUND: Almost 20% of patients with active Crohn's disease are refractory to conventional therap...
AbstractCrohn's disease (CD) presents a great challenge regarding treatment, considering that the be...
Crohn's disease (CD) presents a great challenge regarding treatment, considering that the best drugs...
OBJECTIVE: Infliximab is an effective treatment for refractory or fistulizing Crohn's disease (CD). ...
Background a nd A ims: I nfliximab (IFX), adalimumab (ADA)and certolizumab pegol (CZP) have similar ...
Background and Aims: The three anti-TNF agents infliximab (IFX), adalimumab (ADA) andcertolizumab pe...
BACKGROUND: Infliximab (IFX), adalimumab (ADA), and certolizumab pegol (CZP) have similar efficacy i...
© 2018 Nik Sheng DingCrohn’s disease is a chronic, disabling inflammatory condition that affects the...
Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and...
The arrival of anti-tumor necrosis factor (TNF) agents has led to a dramatic improvement in the care...
BACKGROUND: Anti-TNF drugs are effective treatments for the management of Crohn's disease but treatm...
INTRODUCTION: There is currently an increasing use of biological agents in the management of Crohn's...
Objectives: Crohn’s disease is a chronic, relapsing inflammatory disease of the gastro-intestinal tr...
OBJECTIVE: The aim of this study was to assess our clinical experience with infliximab, a monoclonal...
BACKGROUND: Anti-TNF drugs are effective treatments for the management of Crohn's disease but treatm...
BACKGROUND: Almost 20% of patients with active Crohn's disease are refractory to conventional therap...